IS7738A - Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum. - Google Patents

Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum.

Info

Publication number: IS7738A
Authority: IS; Iceland
Prior art keywords: treatment; neurodegenerative disorders; thiazole compounds; thiazole; compounds
Prior art date: 2002-10-09

Application number

IS7738A

Other languages

English (en)

Inventor

Yuhpyng Linang Chen

Michael Leon Corman

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-09

Filing date

2005-03-10

Publication date

2005-03-10

2005-03-10 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2005-03-10 Publication of IS7738A publication Critical patent/IS7738A/is

Links

208000015122 neurodegenerative disease Diseases 0.000 title 1
150000003557 thiazoles Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

IS7738A 2002-10-09 2005-03-10 Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum. IS7738A (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41740002P	2002-10-09	2002-10-09
US50905903P	2003-06-17	2003-06-17
PCT/IB2003/004330 WO2004033439A1 (en)	2002-10-09	2003-09-29	Thiazole compounds for the treatment of neurodegenerative disorders

Publications (1)

Publication Number	Publication Date
IS7738A true IS7738A (is)	2005-03-10

Family

ID=35306299

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7738A IS7738A (is)	2002-10-09	2005-03-10	Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum.

Country Status (28)

Country	Link
US (1)	US20040152747A1 (is)
EP (1)	EP1551815A1 (is)
JP (1)	JP2006504796A (is)
KR (1)	KR20050070046A (is)
CN (1)	CN1688557A (is)
AP (1)	AP2005003274A0 (is)
AR (1)	AR043051A1 (is)
AU (1)	AU2003265068A1 (is)
BR (1)	BR0314611A (is)
CA (1)	CA2501803A1 (is)
CO (1)	CO5550435A2 (is)
CR (1)	CR7785A (is)
EC (1)	ECSP055719A (is)
GT (1)	GT200300219A (is)
IS (1)	IS7738A (is)
MA (1)	MA27451A1 (is)
MX (1)	MXPA05002420A (is)
NL (1)	NL1024499C2 (is)
NO (1)	NO20052223L (is)
OA (1)	OA12937A (is)
PA (1)	PA8585001A1 (is)
PE (1)	PE20040640A1 (is)
PL (1)	PL376171A1 (is)
TN (1)	TNSN05104A1 (is)
TW (1)	TW200420550A (is)
UY (1)	UY28011A1 (is)
WO (1)	WO2004033439A1 (is)
ZA (1)	ZA200502841B (is)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2842523A1 (fr) *	2002-07-17	2004-01-23	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
MXPA05012196A (es) *	2003-05-12	2006-02-08	Pfizer Prod Inc	Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
EP1653952A4 (en) *	2003-08-06	2007-04-04	Pfizer Prod Inc	OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
WO2005073202A1 (fr) *	2004-01-16	2005-08-11	Sanofi-Aventis	Derives d’acylaminothiazole et leur application comme inhibiteurs de beta-amyloide
JP2007517840A (ja) *	2004-01-16	2007-07-05	サノフイ−アベンテイス	アシルアミノチアゾール誘導体、それらの調製方法及び治療における該誘導体の使用
FR2873374B1 (fr) *	2004-07-22	2006-10-20	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2865206B1 (fr) *	2004-01-16	2009-02-06	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2873370B1 (fr) *	2004-07-22	2006-10-20	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2865207B1 (fr) *	2004-01-16	2008-10-17	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
EP1730119B1 (en) *	2004-03-23	2008-06-25	Pfizer Products Incorporated	Imidazole compounds for the treatment of neurodegenerative disorders
US7384968B2 (en) *	2004-04-01	2008-06-10	Pfizer Inc.	Thiazole-amine compounds for the treatment of neurodegenerative disorders
US7220865B2 (en) *	2004-04-01	2007-05-22	Pfizer Inc	Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
ES2401138T3 (es)	2004-08-13	2013-04-17	Genentech, Inc.	Inhibidores basados en tiazol de enzimas que usan ATP
BRPI0611029A2 (pt) *	2005-05-24	2010-08-10	Serono Lab	derivados de tiazol e uso dos mesmos
FR2887879B1 (fr) *	2005-07-01	2008-09-26	Trophos Sa	Nouveaux composes chimiques et leurs utilisations comme medicament,particulierement dans le traitement des maladies neurodegeneratives
JP2009508934A (ja) *	2005-09-22	2009-03-05	ファイザー・プロダクツ・インク	神経障害治療のためのイミダゾール化合物
EP1968597A4 (en)	2005-12-01	2012-01-11	Scripps Research Inst	COMPOSITIONS AND METHODS FOR INDUCTION OF NEURON DIFFERENTIATION
EP1981884B1 (en) *	2006-01-18	2012-06-13	Amgen, Inc	Thiazole compounds as protein kinase b (pkb) inhibitors
EP1918286B1 (en) *	2006-11-05	2011-12-21	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Thiazolhydrazides for treatment of neurodegenerative diseases
GB0701426D0 (en) *	2007-01-25	2007-03-07	Univ Sheffield	Compounds and their use
WO2009011880A2 (en)	2007-07-17	2009-01-22	Amgen Inc.	Heterocyclic modulators of pkb
WO2009011871A2 (en) *	2007-07-17	2009-01-22	Amgen Inc.	Thiadiazole modulators of pkb
RU2401837C2 (ru) *	2008-05-19	2010-10-20	Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава)	N-(2-тиазолил)амид 2-(2-оксо-3-индолинилиден)гидразино-4-оксо-4-фенил-2-бутеновой кислоты, обладающий противомикробной и анальгетической активностью
TW201006832A (en)	2008-07-15	2010-02-16	Novartis Ag	Organic compounds
JP5705748B2 (ja)	2009-02-18	2015-04-22	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を変調する複素環化合物
WO2010126002A1 (ja) *	2009-04-28	2010-11-04	塩野義製薬株式会社	ヘテロ環スルホンアミド化合物を含有する医薬
US8299103B2 (en) *	2009-06-15	2012-10-30	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the CB2 receptor
WO2011088015A1 (en)	2010-01-15	2011-07-21	Boehringer Ingelheim International Gmbh	Compounds which modulate the cb2 receptor
US8846936B2 (en)	2010-07-22	2014-09-30	Boehringer Ingelheim International Gmbh	Sulfonyl compounds which modulate the CB2 receptor
CN102351854B (zh) *	2011-07-29	2014-06-04	华中科技大学	氨基噻唑衍生物及制备方法和医药用途
SI2970272T1 (sl) *	2013-03-14	2019-06-28	Merck Patent Gmbh	Inhibitorji glikozidaze
EP2803668A1 (en)	2013-05-17	2014-11-19	Boehringer Ingelheim International Gmbh	Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN103435573B (zh) *	2013-07-16	2015-04-01	浙江医药高等专科学校	苄基取代的噻唑并环己烷类化合物、其制备方法和用途
CN103408541B (zh) *	2013-07-16	2015-04-01	浙江医药高等专科学校	吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
GB201401886D0 (en) *	2014-02-04	2014-03-19	Lytix Biopharma As	Neurodegenerative therapies
JP7134173B2 (ja) *	2017-06-21	2022-09-09	第一三共株式会社	Ｅｐ３００／ｃｒｅｂｂｐ阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2102890A1 (en) *	1991-05-28	1992-11-29	Soumya P. Sahoo	Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
WO1999057098A2 (en) *	1998-05-01	1999-11-11	Abbott Laboratories	Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
CO5021134A1 (es) *	1998-05-01	2001-03-27	Abbott Lab	Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
AU6229699A (en) *	1998-10-26	2000-05-15	Sumitomo Pharmaceuticals Company, Limited	Beta-amyloid formation inhibitors
AR039059A1 (es) *	2001-08-06	2005-02-09	Sanofi Aventis	Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2842523A1 (fr) *	2002-07-17	2004-01-23	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

2003
- 2003-09-29 CA CA002501803A patent/CA2501803A1/en not_active Abandoned
- 2003-09-29 OA OA1200500098A patent/OA12937A/en unknown
- 2003-09-29 AP AP2005003274A patent/AP2005003274A0/xx unknown
- 2003-09-29 BR BR0314611-1A patent/BR0314611A/pt not_active IP Right Cessation
- 2003-09-29 PL PL03376171A patent/PL376171A1/xx not_active Application Discontinuation
- 2003-09-29 EP EP03807933A patent/EP1551815A1/en not_active Withdrawn
- 2003-09-29 MX MXPA05002420A patent/MXPA05002420A/es not_active Application Discontinuation
- 2003-09-29 KR KR1020057006168A patent/KR20050070046A/ko not_active Ceased
- 2003-09-29 JP JP2005501002A patent/JP2006504796A/ja active Pending
- 2003-09-29 AU AU2003265068A patent/AU2003265068A1/en not_active Abandoned
- 2003-09-29 WO PCT/IB2003/004330 patent/WO2004033439A1/en not_active Ceased
- 2003-09-29 CN CNA038240106A patent/CN1688557A/zh active Pending
- 2003-10-03 TW TW092127495A patent/TW200420550A/zh unknown
- 2003-10-07 PE PE2003001021A patent/PE20040640A1/es not_active Application Discontinuation
- 2003-10-08 US US10/682,686 patent/US20040152747A1/en not_active Abandoned
- 2003-10-08 PA PA20038585001A patent/PA8585001A1/es unknown
- 2003-10-08 AR ARP030103662A patent/AR043051A1/es unknown
- 2003-10-09 GT GT200300219A patent/GT200300219A/es unknown
- 2003-10-09 UY UY28011A patent/UY28011A1/es not_active Application Discontinuation
- 2003-10-09 NL NL1024499A patent/NL1024499C2/nl not_active IP Right Cessation
2005
- 2005-03-10 IS IS7738A patent/IS7738A/is unknown
- 2005-04-07 CR CR7785A patent/CR7785A/es not_active Application Discontinuation
- 2005-04-07 EC EC2005005719A patent/ECSP055719A/es unknown
- 2005-04-08 TN TNP2005000104A patent/TNSN05104A1/fr unknown
- 2005-04-08 MA MA28206A patent/MA27451A1/fr unknown
- 2005-04-08 CO CO05031337A patent/CO5550435A2/es not_active Application Discontinuation
- 2005-05-06 NO NO20052223A patent/NO20052223L/no unknown
2006
- 2006-01-17 ZA ZA200502841A patent/ZA200502841B/en unknown

Also Published As

Publication number	Publication date
ZA200502841B (en)	2006-03-29
JP2006504796A (ja)	2006-02-09
EP1551815A1 (en)	2005-07-13
OA12937A (en)	2006-10-13
PA8585001A1 (es)	2004-12-16
AR043051A1 (es)	2005-07-13
AU2003265068A1 (en)	2004-05-04
CA2501803A1 (en)	2004-04-22
NL1024499C2 (nl)	2004-10-13
PL376171A1 (en)	2005-12-27
NL1024499A1 (nl)	2004-04-13
TNSN05104A1 (fr)	2007-05-14
CN1688557A (zh)	2005-10-26
NO20052223L (no)	2005-07-04
AP2005003274A0 (en)	2005-06-30
WO2004033439A1 (en)	2004-04-22
ECSP055719A (es)	2005-07-06
TW200420550A (en)	2004-10-16
CO5550435A2 (es)	2005-08-31
GT200300219A (es)	2004-05-18
NO20052223D0 (no)	2005-05-06
UY28011A1 (es)	2004-04-30
KR20050070046A (ko)	2005-07-05
BR0314611A (pt)	2005-07-26
MXPA05002420A (es)	2005-10-05
PE20040640A1 (es)	2004-09-15
MA27451A1 (fr)	2005-07-01
CR7785A (es)	2005-07-08
US20040152747A1 (en)	2004-08-05

Publication	Publication Date	Title
IS7738A (is)	2005-03-10	Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum.
DK1474416T3 (da)	2008-01-14	Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
IS8142A (is)	2005-11-23	Læknislyf gagnleg til meðferðar á verkjum
IS8550A (is)	2006-10-09	Imídasól efnasambönd til meðhöndlunar á taugahrörnunarsjúkdómum
DK1343773T3 (da)	2007-02-05	Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
NO20053211D0 (no)	2005-06-30	Forbindelser for behandling av metabolske forstyrrelser.
IS7814A (is)	2005-04-20	Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
IS8267A (is)	2006-01-26	[1,8]naftýridín-2-ón og tengd efnasambönd til notkunar við meðferð á geðklofa
DK1803718T3 (da)	2008-10-27	4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
IS2722B (is)	2011-03-15	1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
IS7099A (is)	2004-01-08	Efnasambönd til að meðhöndla bólgutruflanir
IS7710A (is)	2005-02-24	Heterósýklísk setin píperasín til notkunar við meðferð á geðklofa
IS8275A (is)	2006-01-31	Píperasín afleiður til meðhöndlunar á HIV sýkingum
DK1499730T3 (da)	2014-01-13	Immunokonjugater til behandling af tumorer
IS8246A (is)	2006-01-19	Meðferð á taugahrörnunarástandi
DK1491212T3 (da)	2012-10-29	Middel til behandling af søvnforstyrrelser
IS7137A (is)	2004-01-30	Samsett meðferð til meðhöndlunar á krabbameini
IS7444A (is)	2004-09-13	Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
DE502004010131D1 (de)	2009-11-05	Pyridopyrimidinone zur behandlung von krebserkrankungen
IS7858A (is)	2005-05-23	Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD)
ES1053304Y (es)	2003-07-16	Disposicion mejorada para la fijacion de fregaderos.
IS8511A (is)	2006-06-15	Píperasín gagnleg til meðferðar á verkjum
DK1689706T3 (da)	2017-04-03	Alfa, beta-umættede sulfoxider til behandling af proliferative forstyrrelser
DE60329308D1 (de)	2009-10-29	Oberflächenbehandlung
EP1653952A4 (en)	2007-04-04	OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER